Brokerages predict that Abeona Therapeutics Inc. (NASDAQ:ABEO) will announce sales of $230,000.00 for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Abeona Therapeutics’ earnings, with the lowest sales estimate coming in at $200,000.00 and the highest estimate coming in at $250,000.00. Abeona Therapeutics reported sales of $180,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 27.8%. The company is expected to announce its next quarterly earnings report on Monday, November 13th.

On average, analysts expect that Abeona Therapeutics will report full-year sales of $230,000.00 for the current fiscal year, with estimates ranging from $800,000.00 to $930,000.00. For the next fiscal year, analysts anticipate that the business will report sales of $1.26 million per share, with estimates ranging from $800,000.00 to $1.72 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.07). The business had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.21 million. Abeona Therapeutics had a negative net margin of 2,746.38% and a negative return on equity of 26.66%.

A number of analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $30.00 price objective (up previously from $20.00) on shares of Abeona Therapeutics in a report on Monday, October 16th. Cantor Fitzgerald lifted their target price on shares of Abeona Therapeutics from $21.00 to $34.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 11th. Citigroup Inc. began coverage on shares of Abeona Therapeutics in a research report on Tuesday, October 10th. They issued a “buy” rating and a $32.00 price objective for the company. Royal Bank Of Canada began coverage on shares of Abeona Therapeutics in a research report on Thursday, September 14th. They issued an “outperform” rating and a $23.00 price objective for the company. Finally, Maxim Group set a $17.00 price objective on shares of Abeona Therapeutics and gave the company a “buy” rating in a research report on Tuesday, August 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $22.56.

COPYRIGHT VIOLATION NOTICE: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/10/27/230000-00-in-sales-expected-for-abeona-therapeutics-inc-abeo-this-quarter.html.

Abeona Therapeutics (ABEO) opened at 17.40 on Friday. The stock’s 50 day moving average is $16.55 and its 200 day moving average is $9.48. The firm’s market capitalization is $700.99 million. Abeona Therapeutics has a 1-year low of $4.05 and a 1-year high of $22.75.

Several large investors have recently modified their holdings of ABEO. State of Wisconsin Investment Board bought a new position in shares of Abeona Therapeutics in the 2nd quarter worth approximately $122,000. Rhumbline Advisers purchased a new stake in Abeona Therapeutics in the 2nd quarter worth approximately $190,000. Bank of New York Mellon Corp increased its holdings in Abeona Therapeutics by 125.8% in the 1st quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 23,358 shares in the last quarter. Schwab Charles Investment Management Inc. purchased a new stake in Abeona Therapeutics in the 2nd quarter worth approximately $264,000. Finally, California State Teachers Retirement System purchased a new stake in Abeona Therapeutics in the 2nd quarter worth approximately $275,000. Hedge funds and other institutional investors own 34.15% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.